Global Drug-Eluting Stents Market to Reach $11.7 Billion by 2030

2023-02-14

NEW YORK, Feb. 14, 2023 /PRNewswire/ -- The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Drug-Eluting Stents Market to Reach $11.7 Billion by 2030

Preview

来源: PRNewswire

Read the full report: https://www.reportlinker.com/p05443570/?utm_source=PRN

Global Drug-Eluting Stents Market to Reach $11.7 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Drug-Eluting Stents estimated at US$7.3 Billion in the year 2022, is projected to reach a revised size of US$11.7 Billion by 2030, growing at aCAGR of 6% over the period 2022-2030. Polymer-Free, one of the segments analyzed in the report, is projected to record 6.3% CAGR and reach US$7.9 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Polymer-based segment is readjusted to a revised 5.5% CAGR for the next 8-year period.

The U.S. Market is Estimated at $2 Billion, While China is Forecast to Grow at 9.9% CAGR

The Drug-Eluting Stents market in the U.S. is estimated at US$2 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.6 Billion by the year 2030 trailing a CAGR of 9.9% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.2% and 6.4% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 3.4% CAGR.

Select Competitors (Total 33 Featured)

- Abbott Laboratories

- AlviMedica

- Arterius Limited

- Biotronik SE

- Boston Scientific Corporation

- Cook Medical

- Medtronic plc

- STENTYS SA

- Terumo Corporation

Read the full report: https://www.reportlinker.com/p05443570/?utm_source=PRN

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Influencer Market Insights

World Market Trajectories

Coronary Stents Market - A Prelude

Recent Market Activity

Competitive Scenario

J&J Exit from DES Market Improves Prospects for Competitors

Evolution of the Drug-Eluting Stent

Evolution of Drug-Eluting Stents (DES) Over the Years

Comparative Analysis of Drug-Eluting Stents in Terms of

Physical Parameters

Bioabsorbable Stents

New Stents with Biodegradable Polymers

Completely Bioresorbable Scaffolds: Potential Game-Changer

Noteworthy Clinical Studies and Innovations

Study Proves Efficacy of Very Thin Strut DES On Par with

Durable Polymer Stents

Drug-Eluting Stents and Drug-Coated Balloons for Non-Coronary

Indications

DES for Large Sized Arteries

Addressing the Unmet Challenges in Patients with Diabetes

Biosensors Commercializes BMX-J DES System

SLENDER DES Set to Downsize the Future of Interventional

Cardiology

Other Novel DES Launches

Researchers at University of Strathclyde Evaluate VAN 10-4

Small Molecule

DES Safe for Vein Grafts Procedures

Drug-Eluting Stents - Global Key Competitors Percentage Market

Share in 2022 (E)

Competitive Market Presence - Strong/Active/Niche/Trivial for

Players Worldwide in 2022 (E)

Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

Key Market Drivers & Restraints

Aging - A Key Market Driver

Global Aging Population Demographic Statistics: Key Opportunity

Indicator

High Diabetes Incidence Worldwide Drives Demand for Cardiac

Surgery and Stents

4. GLOBAL MARKET PERSPECTIVE

Table 1: World Recent Past, Current & Future Analysis for

Drug-Eluting Stents by Geographic Region - USA, Canada, Japan,

China, Europe, Asia-Pacific, Latin America, Middle East and

Africa Markets - Independent Analysis of Annual Sales in US$

Million for Years 2022 through 2030 and % CAGR

Table 2: World Historic Review for Drug-Eluting Stents by

Geographic Region - USA, Canada, Japan, China, Europe,

Asia-Pacific, Latin America, Middle East and Africa Markets -

Independent Analysis of Annual Sales in US$ Million for Years

2014 through 2021 and % CAGR

Table 3: World 16-Year Perspective for Drug-Eluting Stents by

Geographic Region - Percentage Breakdown of Value Sales for

USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,

Middle East and Africa Markets for Years 2014, 2023 & 2030

Table 4: World Recent Past, Current & Future Analysis for

Polymer-Free by Geographic Region - USA, Canada, Japan, China,

Europe, Asia-Pacific, Latin America, Middle East and Africa

Markets - Independent Analysis of Annual Sales in US$ Million

for Years 2022 through 2030 and % CAGR

Table 5: World Historic Review for Polymer-Free by Geographic

Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin

America, Middle East and Africa Markets - Independent Analysis

of Annual Sales in US$ Million for Years 2014 through 2021 and

% CAGR

Table 6: World 16-Year Perspective for Polymer-Free by

Geographic Region - Percentage Breakdown of Value Sales for

USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,

Middle East and Africa for Years 2014, 2023 & 2030

Table 7: World Recent Past, Current & Future Analysis for

Polymer-based by Geographic Region - USA, Canada, Japan, China,

Europe, Asia-Pacific, Latin America, Middle East and Africa

Markets - Independent Analysis of Annual Sales in US$ Million

for Years 2022 through 2030 and % CAGR

Table 8: World Historic Review for Polymer-based by Geographic

Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin

America, Middle East and Africa Markets - Independent Analysis

of Annual Sales in US$ Million for Years 2014 through 2021 and

% CAGR

Table 9: World 16-Year Perspective for Polymer-based by

Geographic Region - Percentage Breakdown of Value Sales for

USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,

Middle East and Africa for Years 2014, 2023 & 2030

Table 10: World Recent Past, Current & Future Analysis for

Coronary Artery Disease by Geographic Region - USA, Canada,

Japan, China, Europe, Asia-Pacific, Latin America, Middle East

and Africa Markets - Independent Analysis of Annual Sales in

US$ Million for Years 2022 through 2030 and % CAGR

Table 11: World Historic Review for Coronary Artery Disease by

Geographic Region - USA, Canada, Japan, China, Europe,

Asia-Pacific, Latin America, Middle East and Africa Markets -

Independent Analysis of Annual Sales in US$ Million for Years

2014 through 2021 and % CAGR

Table 12: World 16-Year Perspective for Coronary Artery Disease

by Geographic Region - Percentage Breakdown of Value Sales for

USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,

Middle East and Africa for Years 2014, 2023 & 2030

Table 13: World Recent Past, Current & Future Analysis for

Peripheral Artery Disease by Geographic Region - USA, Canada,

Japan, China, Europe, Asia-Pacific, Latin America, Middle East

and Africa Markets - Independent Analysis of Annual Sales in

US$ Million for Years 2022 through 2030 and % CAGR

Table 14: World Historic Review for Peripheral Artery Disease

by Geographic Region - USA, Canada, Japan, China, Europe,

Asia-Pacific, Latin America, Middle East and Africa Markets -

Independent Analysis of Annual Sales in US$ Million for Years

2014 through 2021 and % CAGR

Table 15: World 16-Year Perspective for Peripheral Artery

Disease by Geographic Region - Percentage Breakdown of Value

Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,

Latin America, Middle East and Africa for Years 2014, 2023 &

2030

Table 16: World Recent Past, Current & Future Analysis for

Cardiology Centers by Geographic Region - USA, Canada, Japan,

China, Europe, Asia-Pacific, Latin America, Middle East and

Africa Markets - Independent Analysis of Annual Sales in US$

Million for Years 2022 through 2030 and % CAGR

Table 17: World Historic Review for Cardiology Centers by

Geographic Region - USA, Canada, Japan, China, Europe,

Asia-Pacific, Latin America, Middle East and Africa Markets -

Independent Analysis of Annual Sales in US$ Million for Years

2014 through 2021 and % CAGR

Table 18: World 16-Year Perspective for Cardiology Centers by

Geographic Region - Percentage Breakdown of Value Sales for

USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,

Middle East and Africa for Years 2014, 2023 & 2030

Table 19: World Recent Past, Current & Future Analysis for

Hospitals by Geographic Region - USA, Canada, Japan, China,

Europe, Asia-Pacific, Latin America, Middle East and Africa

Markets - Independent Analysis of Annual Sales in US$ Million

for Years 2022 through 2030 and % CAGR

Table 20: World Historic Review for Hospitals by Geographic

Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin

America, Middle East and Africa Markets - Independent Analysis

of Annual Sales in US$ Million for Years 2014 through 2021 and

% CAGR

Table 21: World 16-Year Perspective for Hospitals by Geographic

Region - Percentage Breakdown of Value Sales for USA, Canada,

Japan, China, Europe, Asia-Pacific, Latin America, Middle East

and Africa for Years 2014, 2023 & 2030

Table 22: World Recent Past, Current & Future Analysis for

Ambulatory Surgery Centers by Geographic Region - USA, Canada,

Japan, China, Europe, Asia-Pacific, Latin America, Middle East

and Africa Markets - Independent Analysis of Annual Sales in

US$ Million for Years 2022 through 2030 and % CAGR

Table 23: World Historic Review for Ambulatory Surgery Centers

by Geographic Region - USA, Canada, Japan, China, Europe,

Asia-Pacific, Latin America, Middle East and Africa Markets -

Independent Analysis of Annual Sales in US$ Million for Years

2014 through 2021 and % CAGR

Table 24: World 16-Year Perspective for Ambulatory Surgery

Centers by Geographic Region - Percentage Breakdown of Value

Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,

Latin America, Middle East and Africa for Years 2014, 2023 &

2030

Table 25: World Drug-Eluting Stents Market Analysis of Annual

Sales in US$ Million for Years 2014 through 2030

III. MARKET ANALYSIS

UNITED STATES

Drug-Eluting Stents Market Presence - Strong/Active/Niche/

Trivial - Key Competitors in the United States for 2023 (E)

Table 26: USA Recent Past, Current & Future Analysis for

Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based -

Independent Analysis of Annual Sales in US$ Million for the

Years 2022 through 2030 and % CAGR

Table 27: USA Historic Review for Drug-Eluting Stents by

Coating - Polymer-Free and Polymer-based Markets - Independent

Analysis of Annual Sales in US$ Million for Years 2014 through

2021 and % CAGR

Table 28: USA 16-Year Perspective for Drug-Eluting Stents by

Coating - Percentage Breakdown of Value Sales for Polymer-Free

and Polymer-based for the Years 2014, 2023 & 2030

Table 29: USA Recent Past, Current & Future Analysis for

Drug-Eluting Stents by Application - Coronary Artery Disease

and Peripheral Artery Disease - Independent Analysis of Annual

Sales in US$ Million for the Years 2022 through 2030 and % CAGR

Table 30: USA Historic Review for Drug-Eluting Stents by

Application - Coronary Artery Disease and Peripheral Artery

Disease Markets - Independent Analysis of Annual Sales in US$

Million for Years 2014 through 2021 and % CAGR

Table 31: USA 16-Year Perspective for Drug-Eluting Stents by

Application - Percentage Breakdown of Value Sales for Coronary

Artery Disease and Peripheral Artery Disease for the Years

2014, 2023 & 2030

Table 32: USA Recent Past, Current & Future Analysis for

Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory

Surgery Centers and Hospitals - Independent Analysis of Annual

Sales in US$ Million for the Years 2022 through 2030 and % CAGR

Table 33: USA Historic Review for Drug-Eluting Stents by

End-Use - Cardiology Centers, Ambulatory Surgery Centers and

Hospitals Markets - Independent Analysis of Annual Sales in US$

Million for Years 2014 through 2021 and % CAGR

Table 34: USA 16-Year Perspective for Drug-Eluting Stents by

End-Use - Percentage Breakdown of Value Sales for Cardiology

Centers, Ambulatory Surgery Centers and Hospitals for the Years

2014, 2023 & 2030

CANADA

Table 35: Canada Recent Past, Current & Future Analysis for

Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based -

Independent Analysis of Annual Sales in US$ Million for the

Years 2022 through 2030 and % CAGR

Table 36: Canada Historic Review for Drug-Eluting Stents by

Coating - Polymer-Free and Polymer-based Markets - Independent

Analysis of Annual Sales in US$ Million for Years 2014 through

2021 and % CAGR

Table 37: Canada 16-Year Perspective for Drug-Eluting Stents by

Coating - Percentage Breakdown of Value Sales for Polymer-Free

and Polymer-based for the Years 2014, 2023 & 2030

Table 38: Canada Recent Past, Current & Future Analysis for

Drug-Eluting Stents by Application - Coronary Artery Disease

and Peripheral Artery Disease - Independent Analysis of Annual

Sales in US$ Million for the Years 2022 through 2030 and % CAGR

Table 39: Canada Historic Review for Drug-Eluting Stents by

Application - Coronary Artery Disease and Peripheral Artery

Disease Markets - Independent Analysis of Annual Sales in US$

Million for Years 2014 through 2021 and % CAGR

Table 40: Canada 16-Year Perspective for Drug-Eluting Stents by

Application - Percentage Breakdown of Value Sales for Coronary

Artery Disease and Peripheral Artery Disease for the Years

2014, 2023 & 2030

Table 41: Canada Recent Past, Current & Future Analysis for

Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory

Surgery Centers and Hospitals - Independent Analysis of Annual

Sales in US$ Million for the Years 2022 through 2030 and % CAGR

Table 42: Canada Historic Review for Drug-Eluting Stents by

End-Use - Cardiology Centers, Ambulatory Surgery Centers and

Hospitals Markets - Independent Analysis of Annual Sales in US$

Million for Years 2014 through 2021 and % CAGR

Table 43: Canada 16-Year Perspective for Drug-Eluting Stents by

End-Use - Percentage Breakdown of Value Sales for Cardiology

Centers, Ambulatory Surgery Centers and Hospitals for the Years

2014, 2023 & 2030

JAPAN

Drug-Eluting Stents Market Presence - Strong/Active/Niche/

Trivial - Key Competitors in Japan for 2023 (E)

Table 44: Japan Recent Past, Current & Future Analysis for

Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based -

Independent Analysis of Annual Sales in US$ Million for the

Years 2022 through 2030 and % CAGR

Table 45: Japan Historic Review for Drug-Eluting Stents by

Coating - Polymer-Free and Polymer-based Markets - Independent

Analysis of Annual Sales in US$ Million for Years 2014 through

2021 and % CAGR

Table 46: Japan 16-Year Perspective for Drug-Eluting Stents by

Coating - Percentage Breakdown of Value Sales for Polymer-Free

and Polymer-based for the Years 2014, 2023 & 2030

Table 47: Japan Recent Past, Current & Future Analysis for

Drug-Eluting Stents by Application - Coronary Artery Disease

and Peripheral Artery Disease - Independent Analysis of Annual

Sales in US$ Million for the Years 2022 through 2030 and % CAGR

Table 48: Japan Historic Review for Drug-Eluting Stents by

Application - Coronary Artery Disease and Peripheral Artery

Disease Markets - Independent Analysis of Annual Sales in US$

Million for Years 2014 through 2021 and % CAGR

Table 49: Japan 16-Year Perspective for Drug-Eluting Stents by

Application - Percentage Breakdown of Value Sales for Coronary

Artery Disease and Peripheral Artery Disease for the Years

2014, 2023 & 2030

Table 50: Japan Recent Past, Current & Future Analysis for

Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory

Surgery Centers and Hospitals - Independent Analysis of Annual

Sales in US$ Million for the Years 2022 through 2030 and % CAGR

Table 51: Japan Historic Review for Drug-Eluting Stents by

End-Use - Cardiology Centers, Ambulatory Surgery Centers and

Hospitals Markets - Independent Analysis of Annual Sales in US$

Million for Years 2014 through 2021 and % CAGR

Table 52: Japan 16-Year Perspective for Drug-Eluting Stents by

End-Use - Percentage Breakdown of Value Sales for Cardiology

Centers, Ambulatory Surgery Centers and Hospitals for the Years

2014, 2023 & 2030

CHINA

Drug-Eluting Stents Market Presence - Strong/Active/Niche/

Trivial - Key Competitors in China for 2023 (E)

Table 53: China Recent Past, Current & Future Analysis for

Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based -

Independent Analysis of Annual Sales in US$ Million for the

Years 2022 through 2030 and % CAGR

Table 54: China Historic Review for Drug-Eluting Stents by

Coating - Polymer-Free and Polymer-based Markets - Independent

Analysis of Annual Sales in US$ Million for Years 2014 through

2021 and % CAGR

Table 55: China 16-Year Perspective for Drug-Eluting Stents by

Coating - Percentage Breakdown of Value Sales for Polymer-Free

and Polymer-based for the Years 2014, 2023 & 2030

Table 56: China Recent Past, Current & Future Analysis for

Drug-Eluting Stents by Application - Coronary Artery Disease

and Peripheral Artery Disease - Independent Analysis of Annual

Sales in US$ Million for the Years 2022 through 2030 and % CAGR

Table 57: China Historic Review for Drug-Eluting Stents by

Application - Coronary Artery Disease and Peripheral Artery

Disease Markets - Independent Analysis of Annual Sales in US$

Million for Years 2014 through 2021 and % CAGR

Table 58: China 16-Year Perspective for Drug-Eluting Stents by

Application - Percentage Breakdown of Value Sales for Coronary

Artery Disease and Peripheral Artery Disease for the Years

2014, 2023 & 2030

Table 59: China Recent Past, Current & Future Analysis for

Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory

Surgery Centers and Hospitals - Independent Analysis of Annual

Sales in US$ Million for the Years 2022 through 2030 and % CAGR

Table 60: China Historic Review for Drug-Eluting Stents by

End-Use - Cardiology Centers, Ambulatory Surgery Centers and

Hospitals Markets - Independent Analysis of Annual Sales in US$

Million for Years 2014 through 2021 and % CAGR

Table 61: China 16-Year Perspective for Drug-Eluting Stents by

End-Use - Percentage Breakdown of Value Sales for Cardiology

Centers, Ambulatory Surgery Centers and Hospitals for the Years

2014, 2023 & 2030

EUROPE

Drug-Eluting Stents Market Presence - Strong/Active/Niche/

Trivial - Key Competitors in Europe for 2023 (E)

Table 62: Europe Recent Past, Current & Future Analysis for

Drug-Eluting Stents by Geographic Region - France, Germany,

Italy, UK, Spain, Russia and Rest of Europe Markets -

Independent Analysis of Annual Sales in US$ Million for Years

2022 through 2030 and % CAGR

Table 63: Europe Historic Review for Drug-Eluting Stents by

Geographic Region - France, Germany, Italy, UK, Spain, Russia

and Rest of Europe Markets - Independent Analysis of Annual

Sales in US$ Million for Years 2014 through 2021 and % CAGR

Table 64: Europe 16-Year Perspective for Drug-Eluting Stents by

Geographic Region - Percentage Breakdown of Value Sales for

France, Germany, Italy, UK, Spain, Russia and Rest of Europe

Markets for Years 2014, 2023 & 2030

Table 65: Europe Recent Past, Current & Future Analysis for

Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based -

Independent Analysis of Annual Sales in US$ Million for the

Years 2022 through 2030 and % CAGR

Table 66: Europe Historic Review for Drug-Eluting Stents by

Coating - Polymer-Free and Polymer-based Markets - Independent

Analysis of Annual Sales in US$ Million for Years 2014 through

2021 and % CAGR

Table 67: Europe 16-Year Perspective for Drug-Eluting Stents by

Coating - Percentage Breakdown of Value Sales for Polymer-Free

and Polymer-based for the Years 2014, 2023 & 2030

Table 68: Europe Recent Past, Current & Future Analysis for

Drug-Eluting Stents by Application - Coronary Artery Disease

and Peripheral Artery Disease - Independent Analysis of Annual

Sales in US$ Million for the Years 2022 through 2030 and % CAGR

Table 69: Europe Historic Review for Drug-Eluting Stents by

Application - Coronary Artery Disease and Peripheral Artery

Disease Markets - Independent Analysis of Annual Sales in US$

Million for Years 2014 through 2021 and % CAGR

Table 70: Europe 16-Year Perspective for Drug-Eluting Stents by

Application - Percentage Breakdown of Value Sales for Coronary

Artery Disease and Peripheral Artery Disease for the Years

2014, 2023 & 2030

Table 71: Europe Recent Past, Current & Future Analysis for

Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory

Surgery Centers and Hospitals - Independent Analysis of Annual

Sales in US$ Million for the Years 2022 through 2030 and % CAGR

Table 72: Europe Historic Review for Drug-Eluting Stents by

End-Use - Cardiology Centers, Ambulatory Surgery Centers and

Hospitals Markets - Independent Analysis of Annual Sales in US$

Million for Years 2014 through 2021 and % CAGR

Table 73: Europe 16-Year Perspective for Drug-Eluting Stents by

End-Use - Percentage Breakdown of Value Sales for Cardiology

Centers, Ambulatory Surgery Centers and Hospitals for the Years

2014, 2023 & 2030

FRANCE

Drug-Eluting Stents Market Presence - Strong/Active/Niche/

Trivial - Key Competitors in France for 2023 (E)

Table 74: France Recent Past, Current & Future Analysis for

Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based -

Independent Analysis of Annual Sales in US$ Million for the

Years 2022 through 2030 and % CAGR

Table 75: France Historic Review for Drug-Eluting Stents by

Coating - Polymer-Free and Polymer-based Markets - Independent

Analysis of Annual Sales in US$ Million for Years 2014 through

2021 and % CAGR

Table 76: France 16-Year Perspective for Drug-Eluting Stents by

Coating - Percentage Breakdown of Value Sales for Polymer-Free

and Polymer-based for the Years 2014, 2023 & 2030

Table 77: France Recent Past, Current & Future Analysis for

Drug-Eluting Stents by Application - Coronary Artery Disease

and Peripheral Artery Disease - Independent Analysis of Annual

Sales in US$ Million for the Years 2022 through 2030 and % CAGR

Table 78: France Historic Review for Drug-Eluting Stents by

Application - Coronary Artery Disease and Peripheral Artery

Disease Markets - Independent Analysis of Annual Sales in US$

Million for Years 2014 through 2021 and % CAGR

Table 79: France 16-Year Perspective for Drug-Eluting Stents by

Application - Percentage Breakdown of Value Sales for Coronary

Artery Disease and Peripheral Artery Disease for the Years

2014, 2023 & 2030

Table 80: France Recent Past, Current & Future Analysis for

Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory

Surgery Centers and Hospitals - Independent Analysis of Annual

Sales in US$ Million for the Years 2022 through 2030 and % CAGR

Table 81: France Historic Review for Drug-Eluting Stents by

End-Use - Cardiology Centers, Ambulatory Surgery Centers and

Hospitals Markets - Independent Analysis of Annual Sales in US$

Million for Years 2014 through 2021 and % CAGR

Table 82: France 16-Year Perspective for Drug-Eluting Stents by

End-Use - Percentage Breakdown of Value Sales for Cardiology

Centers, Ambulatory Surgery Centers and Hospitals for the Years

2014, 2023 & 2030

GERMANY

Drug-Eluting Stents Market Presence - Strong/Active/Niche/

Trivial - Key Competitors in Germany for 2023 (E)

Table 83: Germany Recent Past, Current & Future Analysis for

Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based -

Independent Analysis of Annual Sales in US$ Million for the

Years 2022 through 2030 and % CAGR

Table 84: Germany Historic Review for Drug-Eluting Stents by

Coating - Polymer-Free and Polymer-based Markets - Independent

Analysis of Annual Sales in US$ Million for Years 2014 through

2021 and % CAGR

Table 85: Germany 16-Year Perspective for Drug-Eluting Stents

by Coating - Percentage Breakdown of Value Sales for

Polymer-Free and Polymer-based for the Years 2014, 2023 & 2030

Table 86: Germany Recent Past, Current & Future Analysis for

Drug-Eluting Stents by Application - Coronary Artery Disease

and Peripheral Artery Disease - Independent Analysis of Annual

Sales in US$ Million for the Years 2022 through 2030 and % CAGR

Table 87: Germany Historic Review for Drug-Eluting Stents by

Application - Coronary Artery Disease and Peripheral Artery

Disease Markets - Independent Analysis of Annual Sales in US$

Million for Years 2014 through 2021 and % CAGR

Table 88: Germany 16-Year Perspective for Drug-Eluting Stents

by Application - Percentage Breakdown of Value Sales for

Coronary Artery Disease and Peripheral Artery Disease for the

Years 2014, 2023 & 2030

Table 89: Germany Recent Past, Current & Future Analysis for

Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory

Surgery Centers and Hospitals - Independent Analysis of Annual

Sales in US$ Million for the Years 2022 through 2030 and % CAGR

Table 90: Germany Historic Review for Drug-Eluting Stents by

End-Use - Cardiology Centers, Ambulatory Surgery Centers and

Hospitals Markets - Independent Analysis of Annual Sales in US$

Million for Years 2014 through 2021 and % CAGR

Table 91: Germany 16-Year Perspective for Drug-Eluting Stents

by End-Use - Percentage Breakdown of Value Sales for Cardiology

Centers, Ambulatory Surgery Centers and Hospitals for the Years

2014, 2023 & 2030

ITALY

Table 92: Italy Recent Past, Current & Future Analysis for

Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based -

Independent Analysis of Annual Sales in US$ Million for the

Years 2022 through 2030 and % CAGR

Table 93: Italy Historic Review for Drug-Eluting Stents by

Coating - Polymer-Free and Polymer-based Markets - Independent

Analysis of Annual Sales in US$ Million for Years 2014 through

2021 and % CAGR

Table 94: Italy 16-Year Perspective for Drug-Eluting Stents by

Coating - Percentage Breakdown of Value Sales for Polymer-Free

and Polymer-based for the Years 2014, 2023 & 2030

Table 95: Italy Recent Past, Current & Future Analysis for

Drug-Eluting Stents by Application - Coronary Artery Disease

and Peripheral Artery Disease - Independent Analysis of Annual

Sales in US$ Million for the Years 2022 through 2030 and % CAGR

Table 96: Italy Historic Review for Drug-Eluting Stents by

Application - Coronary Artery Disease and Peripheral Artery

Disease Markets - Independent Analysis of Annual Sales in US$

Million for Years 2014 through 2021 and % CAGR

Table 97: Italy 16-Year Perspective for Drug-Eluting Stents by

Application - Percentage Breakdown of Value Sales for Coronary

Artery Disease and Peripheral Artery Disease for the Years

2014, 2023 & 2030

Table 98: Italy Recent Past, Current & Future Analysis for

Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory

Surgery Centers and Hospitals - Independent Analysis of Annual

Sales in US$ Million for the Years 2022 through 2030 and % CAGR

Table 99: Italy Historic Review for Drug-Eluting Stents by

End-Use - Cardiology Centers, Ambulatory Surgery Centers and

Hospitals Markets - Independent Analysis of Annual Sales in US$

Million for Years 2014 through 2021 and % CAGR

Table 100: Italy 16-Year Perspective for Drug-Eluting Stents by

End-Use - Percentage Breakdown of Value Sales for Cardiology

Centers, Ambulatory Surgery Centers and Hospitals for the Years

2014, 2023 & 2030

UNITED KINGDOM

Drug-Eluting Stents Market Presence - Strong/Active/Niche/

Trivial - Key Competitors in the United Kingdom for 2023 (E)

Table 101: UK Recent Past, Current & Future Analysis for

Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based -

Independent Analysis of Annual Sales in US$ Million for the

Years 2022 through 2030 and % CAGR

Table 102: UK Historic Review for Drug-Eluting Stents by

Coating - Polymer-Free and Polymer-based Markets - Independent

Analysis of Annual Sales in US$ Million for Years 2014 through

2021 and % CAGR

Table 103: UK 16-Year Perspective for Drug-Eluting Stents by

Coating - Percentage Breakdown of Value Sales for Polymer-Free

and Polymer-based for the Years 2014, 2023 & 2030

Table 104: UK Recent Past, Current & Future Analysis for

Drug-Eluting Stents by Application - Coronary Artery Disease

and Peripheral Artery Disease - Independent Analysis of Annual

Sales in US$ Million for the Years 2022 through 2030 and % CAGR

Table 105: UK Historic Review for Drug-Eluting Stents by

Application - Coronary Artery Disease and Peripheral Artery

Disease Markets - Independent Analysis of Annual Sales in US$

Million for Years 2014 through 2021 and % CAGR

Table 106: UK 16-Year Perspective for Drug-Eluting Stents by

Application - Percentage Breakdown of Value Sales for Coronary

Artery Disease and Peripheral Artery Disease for the Years

2014, 2023 & 2030

Table 107: UK Recent Past, Current & Future Analysis for

Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory

Surgery Centers and Hospitals - Independent Analysis of Annual

Sales in US$ Million for the Years 2022 through 2030 and % CAGR

Table 108: UK Historic Review for Drug-Eluting Stents by

End-Use - Cardiology Centers, Ambulatory Surgery Centers and

Hospitals Markets - Independent Analysis of Annual Sales in US$

Million for Years 2014 through 2021 and % CAGR

Table 109: UK 16-Year Perspective for Drug-Eluting Stents by

End-Use - Percentage Breakdown of Value Sales for Cardiology

Centers, Ambulatory Surgery Centers and Hospitals for the Years

2014, 2023 & 2030

SPAIN

Table 110: Spain Recent Past, Current & Future Analysis for

Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based -

Independent Analysis of Annual Sales in US$ Million for the

Years 2022 through 2030 and % CAGR

Table 111: Spain Historic Review for Drug-Eluting Stents by

Coating - Polymer-Free and Polymer-based Markets - Independent

Analysis of Annual Sales in US$ Million for Years 2014 through

2021 and % CAGR

Table 112: Spain 16-Year Perspective for Drug-Eluting Stents by

Coating - Percentage Breakdown of Value Sales for Polymer-Free

and Polymer-based for the Years 2014, 2023 & 2030

Table 113: Spain Recent Past, Current & Future Analysis for

Drug-Eluting Stents by Application - Coronary Artery Disease

and Peripheral Artery Disease - Independent Analysis of Annual

Sales in US$ Million for the Years 2022 through 2030 and % CAGR

Table 114: Spain Historic Review for Drug-Eluting Stents by

Application - Coronary Artery Disease and Peripheral Artery

Disease Markets - Independent Analysis of Annual Sales in US$

Million for Years 2014 through 2021 and % CAGR

Table 115: Spain 16-Year Perspective for Drug-Eluting Stents by

Application - Percentage Breakdown of Value Sales for Coronary

Artery Disease and Peripheral Artery Disease for the Years

2014, 2023 & 2030

Table 116: Spain Recent Past, Current & Future Analysis for

Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory

Surgery Centers and Hospitals - Independent Analysis of Annual

Sales in US$ Million for the Years 2022 through 2030 and % CAGR

Table 117: Spain Historic Review for Drug-Eluting Stents by

End-Use - Cardiology Centers, Ambulatory Surgery Centers and

Hospitals Markets - Independent Analysis of Annual Sales in US$

Million for Years 2014 through 2021 and % CAGR

Table 118: Spain 16-Year Perspective for Drug-Eluting Stents by

End-Use - Percentage Breakdown of Value Sales for Cardiology

Centers, Ambulatory Surgery Centers and Hospitals for the Years

2014, 2023 & 2030

RUSSIA

Table 119: Russia Recent Past, Current & Future Analysis for

Drug-Eluting Stents by Coating - Polymer-Free and Polymer-based -

Independent Analysis of Annual Sales in US$ Million for the

Years 2022 through 2030 and % CAGR

Table 120: Russia Historic Review for Drug-Eluting Stents by

Coating - Polymer-Free and Polymer-based Markets - Independent

Analysis of Annual Sales in US$ Million for Years 2014 through

2021 and % CAGR

Table 121: Russia 16-Year Perspective for Drug-Eluting Stents

by Coating - Percentage Breakdown of Value Sales for

Polymer-Free and Polymer-based for the Years 2014, 2023 & 2030

Table 122: Russia Recent Past, Current & Future Analysis for

Drug-Eluting Stents by Application - Coronary Artery Disease

and Peripheral Artery Disease - Independent Analysis of Annual

Sales in US$ Million for the Years 2022 through 2030 and % CAGR

Table 123: Russia Historic Review for Drug-Eluting Stents by

Application - Coronary Artery Disease and Peripheral Artery

Disease Markets - Independent Analysis of Annual Sales in US$

Million for Years 2014 through 2021 and % CAGR

Table 124: Russia 16-Year Perspective for Drug-Eluting Stents

by Application - Percentage Breakdown of Value Sales for

Coronary Artery Disease and Peripheral Artery Disease for the

Years 2014, 2023 & 2030

Table 125: Russia Recent Past, Current & Future Analysis for

Drug-Eluting Stents by End-Use - Cardiology Centers, Ambulatory

Surgery Centers and Hospitals - Independent Analysis of Annual

Sales in US$ Million for the Years 2022 through 2030 and % CAGR

Table 126: Russia Historic Review for Drug-Eluting Stents by

End-Use - Cardiology Centers, Ambulatory Surgery Centers and

Hospitals Markets - Independent Analysis of Annual Sales in US$

Million for Years 2014 through 2021 and % CAGR

Table 127: Russia 16-Year Perspective for Drug-Eluting Stents

by End-Use - Percentage Breakdown of Value Sales for Cardiology

Centers, Ambulatory Surgery Centers and Hospitals for the Years

2014, 2023 & 2030

REST OF EUROPE

Table 128: Rest of Europe Recent Past, Current & Future

Analysis for Drug-Eluting Stents by Coating - Polymer-Free and

Please contact our Customer Support Center to get the complete Table of Contents

Read the full report: https://www.reportlinker.com/p05443570/?utm_source=PRN

About Reportlinker

ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Contact Clare: [email protected]

US: (339)-368-6001

Intl: +1 339-368-6001

SOURCE Reportlinker